Physician profile
Cerin Daniel
NPI 1285098426
$1,615.05
in general payments reported to CMS, 2019-2025
21 companies · $887 in 2025
The $887 reported for 2025 was more than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $160 · 2023: $234 · 2024: $334 · 2025: $887.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,455.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,454.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $299.10 | 2022-2025 | Valtoco |
| Livanova USA, INC. | $250.03 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Ucb, INC. | $155.14 | 2022-2025 | Fintepla |
| Corium, LLC | $152.08 | 2022-2025 | Azstarys |
| Jazz Pharmaceuticals INC. | $142.50 | 2022-2025 | |
| Acadia Pharmaceuticals INC | $125.37 | 2024-2025 | Daybue |
| Azurity Pharmaceuticals, INC. | $66.99 | 2024 | Zonisade |
| Biogen, INC. | $55.30 | 2024-2025 | Spinraza, Skyclarys |
| Tris Pharma INC | $48.21 | 2022-2025 | Onyda Xr |
| Teva Pharmaceuticals USA, INC. | $43.97 | 2025 | Ajovy |
| Noven Therapeutics, LLC | $37.60 | 2023-2024 | Xelstrym |
| Orchard Therapeutics North America | $30.64 | 2025 | Lenmeldy |
| Sumitomo Pharma America, INC. | $30.49 | 2023 | Aptiom |
| Aucta Pharmaceuticals, INC. | $28.78 | 2024 | Motpoly Xr |
| Avadel Cns Pharmaceuticals, LLC | $27.58 | 2025 | Lumryz |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $27.37 | 2022 | |
| Aprecia Pharmaceuticals, LLC | $19.83 | 2022 | |
| Neos Therapeutics, Lp | $19.41 | 2023 | Adzenys Xr-Odt |
| Upsher-Smith Laboratories LLC | $19.08 | 2024 | |
| Aquestive Therapeutics, INC. | $17.88 | 2024 | |
| Catalyst Pharmaceuticals, INC. | $17.70 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cerin Daniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.